<DOC>
	<DOCNO>NCT00073931</DOCNO>
	<brief_summary>RATIONALE : Radiolabeled monoclonal antibody , iodine I 131 tositumomab , locate cancer cell deliver radioactive cancer-killing substance without harm normal cell . Combining radiolabeled monoclonal antibody autologous stem cell transplantation may effective treatment non-Hodgkin 's lymphoma . PURPOSE : Phase II trial study effectiveness combine iodine I 131 tositumomab autologous stem cell transplantation treat old patient relapse refractory non-Hodgkin 's lymphoma .</brief_summary>
	<brief_title>Iodine I 131 Tositumomab Followed Autologous Stem Cell Transplantation Treating Older Patients With Relapsed Refractory Non-Hodgkin 's Lymphoma</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine progression-free survival old patient relapse refractory non-Hodgkin 's lymphoma treat iodine I 131 tositumomab follow autologous stem cell transplantation . Secondary - Determine overall survival patient treat regimen . - Determine toxicity tolerability regimen patient . OUTLINE : - Radioimmunotherapy : Patients receive test dose iodine I 131 tositumomab day -24 determine biodistribution . Patients receive therapeutic iodine I 131 tositumomab IV 1 hour day -14 enter radiation isolation day -4 . - Autologous stem cell transplantation : Patients undergo autologous bone marrow peripheral blood stem cell transplantation day 0 . Patients undergo bone marrow transplantation receive filgrastim ( G-CSF ) sargramostim ( GM-CSF ) subcutaneously begin day 0 continue blood count recover . Patients follow 1 , 3 , 6 , 12 month annually thereafter . PROJECTED ACCRUAL : A total 24-30 patient accrue study within 2 year .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Iodine-131 anti-B1 antibody</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Iodine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm nonHodgkin 's lymphoma CD20+ disease Failed least 1 prior standard systemic therapy Persistent lymphoma physical examination , radiographic study , bone marrow evaluation , flow cytometry , polymerase chain reaction Tumor burden le 500 cc compute tomography MRI No splenomegaly Autologous hematopoietic stem cell bone marrow harvest cryopreserved No circulating lymphoma cell morphology flow cytometry near time peripheral blood stem cell ( PBSC ) collection unpurged PBSCs use 10 % less marrow involvement flow cytometry morphology purge bone marrow use No CNS lymphoma No chronic lymphocytic leukemia small lymphocytic lymphoma/welldifferentiated lymphocytic lymphoma PATIENT CHARACTERISTICS : Age 60 80 Performance status SWOG 01 Life expectancy More 60 day Hematopoietic See Disease Characteristics Hepatic Bilirubin le 1.5 mg/dL Renal Creatinine le 2.0 mg/dL Cardiovascular No active coronary artery disease Pulmonary FEV_1 least 70 % expect Vital capacity least 70 % expect Other Not pregnant Negative pregnancy test Fertile patient must use effective contraception HIV negative Able perform selfcare radiation isolation No major organ dysfunction No major infection No circulating antimouse antibody No serious medical condition consider represent contraindication bone marrow transplantation No compete cause death would predict life span le 10 additional year PRIOR CONCURRENT THERAPY : Biologic therapy No prior bone marrow stem cell transplantation Chemotherapy Not specify Endocrine therapy Not specify Radiotherapy No prior radiotherapy great 20 Gy critical normal organ ( e.g. , lung , liver , spinal cord , 25 % red marrow ) Surgery Not specify Other More 30 day since prior systemic antilymphoma therapy</criteria>
	<gender>All</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>February 2015</verification_date>
	<keyword>recurrent adult diffuse large cell lymphoma</keyword>
	<keyword>recurrent adult diffuse mixed cell lymphoma</keyword>
	<keyword>recurrent adult diffuse small cleave cell lymphoma</keyword>
	<keyword>recurrent adult Burkitt lymphoma</keyword>
	<keyword>recurrent adult immunoblastic large cell lymphoma</keyword>
	<keyword>recurrent adult lymphoblastic lymphoma</keyword>
	<keyword>recurrent grade 1 follicular lymphoma</keyword>
	<keyword>recurrent grade 2 follicular lymphoma</keyword>
	<keyword>recurrent grade 3 follicular lymphoma</keyword>
	<keyword>recurrent mantle cell lymphoma</keyword>
</DOC>